

MEETING AGENDA

Emerging Data on the Role of Wnt Biology in Cancer

The Banbury Center, Cold Spring Harbor Laboratory, New York, USA October 7-10, 2018

This meeting was funded by Leap Therapeutics

Lead Organizers:

Hans Clevers, Hubrecht Institute, Utrecht, Netherlands Roeland Nusse, Stanford University, Stanford, USA Bart Williams, Van Andel Research Institute, Michigan, USA

Supporting Organizers:

David Tuveson, Cold Spring Harbor Laboratory, New York, USA Christopher Mirabelli, Leap Therapeutics, Cambridge, USA Michael Kagey, Leap Therapeutics, Cambridge, USA

This Banbury Center meeting brought together experts in Wnt-related biology, immunology, pharmacology and translational cancer medicine in order to assess the current state of the science, identify emerging themes and prioritize potential therapeutic strategies.

SUNDAY, OCTOBER 7

Afternoon Participant arrivals 6:00 pm Reception, dinner

MONDAY, OCTOBER 8

7:15 am Breakfast





8:30 am Welcome and Introductory Remarks Rebecca Leshan, The Banbury Center, Cold Spring Harbor Laboratory

Roeland Nusse, Stanford University, Stanford, USA Bart Williams, Van Andel Research Institute, Michigan, USA

8:50am SESSION 1: Therapeutic Targeting in Oncology

Lawrence Lum, Pfizer, San Diego, USA David Virshup, Duke NUS Medical School, Singapore, Asia Marilyn Resh, Memorial Sloan Kettering Cancer Center, New York, USA

10:50 am SESSION 2: Regenerative Medicine Applications

Luke Boulter, University of Edinburgh, Edinburgh, UK Yingzi Yang, Harvard School of Dental Medicine, Boston, USA Bart Williams, Van Andel Research Institute, Grand Rapids, USA

12:15 pm Luncheon

2:00 pm SESSION 3: Genetic Screens

Stephane Angers, University of Toronto, Ontario, Canada Rajat Rohatgi, Stanford University School of Medicine, Stanford, USA Yashi Ahmed, Darmouth Medical School, Hanover, USA

3:45 pm SESSION 4: Targeting DKK1

Roberta Faccio, Washington University in St. Louis, USA Al Bothwell, Yale University School of Medicine, New Haven, USA David Wise, New York University Langone Medical Center, New York, USA

5:00 pm General Discussion, Day 1 Wrap-Up

6:00 pm Reception, dinner



TUESDAY, OCTOBER 9

7:15 am Breakfast at Robertson House

- 8:30 am [continued] SESSION 4: Targeting DKK1 Walter Newman, Leap Therapeutics, Cambridge, USA Cyndi Sirard, Leap Therapeutics, Cambridge, USA Mike Kagey, Leap Therapeutics, Cambridge, USA
- 10:15 am SESSION 5: Membrane Receptors and Signalosome Assembly Christof Niehrs, German Cancer Research Center (DKFZ), Heidelberg, Germany Ethan Lee, Vanderbilt University, Nashville, USA Claudia Janda, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

11:30 am General Discussion

- 12.30 pm Luncheon
- 2:00 pm SESSION 6: Modeling Receptors: R-Spondin, Rnf43/Znrf3, and Frizzleds Madelon Maurice, University Medical Center Utrecht, Netherlands Bruno Reversade, A*STAR Institute of Medical Biology, Immunos, Singapore Feng Cong, Novartis Institute for Biomedical Research, Cambridge, USA Austin Gurney, OncoMed Pharmaceuticals, Redwood City, USA
- 4:10 pm SESSION 7: Wnt Signaling and Stem Cells Xi He, Boston Children's Hospital, Boston, USA Marian Waterman, University of California, Irvine, USA Rami Hannoush, Genentech, South San Francisco, USA
- 5:25 pm General Discussion, Day 2 Wrap-Up
- 6:00 pm Reception, dinner



WEDNESDAY, OCTOBER 10

7:15 am Breakfast

- 9:00 am SESSION 8: Emerging Applications for Wnt Signaling in Cancer Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, USA Joan Massagué, Memorial Sloan Kettering Cancer Center, New York, USA Stefani Spranger, Koch Institute for Integrative Cancer Research, Cambridge, USA
- 9:50 am General Discussion
- 10:45 am SESSION 9: Wrap-Up: Conclusions and next Steps Roeland Nusse, Stanford University, Stanford, USA
- 12:15 pm Luncheon
- 2:00 pm Participant departures





MEETING PARTICIPANTS

Yashi Ahmed, Dartmouth Medical School Stephane Angers, University of Toronto Alfred Bothwell, Yale University School of Medicine Luke Boulter, University of Edinburgh Feng Cong, Novartis Institute for Biomedical Research Roberta Faccio, Washington University in St. Louis Austin Gurney, OncoMed Pharmaceuticals Rami Hannoush, Genentech Xi He, Boston Children's Hospital Claudia Janda, Princess Maxima Center for Pediatric Oncology Michael Kagey, Leap Therapeutics Ethan Lee, Vanderbilt University Lawrence Lum, Pfizer Joan Massagué, Memorial Sloan-Kettering Cancer Center Madelon Maurice, University Medical Center Utrecht Christopher Mirabelli, Leap Therapeutics Walter Newman, Leap Therapeutics Christopf Niehrs, German Cancer Research Center (DKFZ) Roeland Nusse, Stanford University Sandeep Ravindran, science writer Marilyn Resh, Memorial Sloan Kettering Cancer Center Bruno Reversade, A*STAR Institute of Medical Biology Rajat Rohatgi, Stanford University School of Medicine Cynthia Sirard, Leap Therapeutics Stefani Spranger, Koch Institute for Integrative Cancer Research Tuomas Tammela, Memorial Sloan Kettering Cancer Center David Tuveson, Cold Spring Harbor Laboratory Harold Varmus, Weill Cornell Medicine David Virshup, Duke-NUS Graduate Medical School Marian Waterman, University of California Irvine Bart Williams, Van Andel Research Institute David Wise, New York University Langone Medical Center Yingzi Yang, Harvard School of Dental Medicine